New attack plan for blood Cancer's comeback
NCT ID NCT05226455
Summary
This study is testing a combination of two drugs (venetoclax and azacitidine) along with an infusion of immune cells from the original stem cell donor. It is for adults whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has come back after a stem cell transplant. The goal is to see if this approach can control the cancer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Hôtel Dieu
Nantes, 44093, France
-
CHU d'Angers
Angers, 49933, France
-
CHU de Grenoble
Grenoble, 38043, France
-
CHU de Haut-Lévèque
Pessac, 33604, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Hôpital Dupuytren
Limoges, 87042, France
-
Hôpital Saint louis
Paris, 75010, France
-
Hôpital Saint-Eloi
Montpellier, 34295, France
-
Hôpital l'Archet I
Nice, 06200, France
-
IUCT Oncopole
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.